eXoZymes Inc
EXOZ
7 hedge funds and large institutions have $682K invested in eXoZymes Inc in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0.03% more ownership
Funds ownership: 0.71% → 0.75% (+0.03%)
22% less capital invested
Capital invested by funds: $880K → $682K (-$198K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$76.3K |
| 2 |
BlackRock
New York
|
+$17.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.88K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$28 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$63.7K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$83 |
EXOZ Hedge Fund Activity: Q4 2025 in Review
7 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in eXoZymes Inc (EXOZ) for Q4 2025, worth a combined $682K — down 22% from $880K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new EXOZ positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $76.3K. The largest seller was UBS Group, cutting an estimated $63.7K.
- 7 institutional investors held eXoZymes Inc (EXOZ) as of Q4 2025, up from 6 in Q3 2025.
- Funds reported $682K of eXoZymes Inc stock for Q4 2025, down 22% quarter-over-quarter.
- 1 fund opened new eXoZymes Inc positions in Q4 2025 and 0 closed out, a net change of +1 holder.
- The largest eXoZymes Inc buyer in Q4 2025 was Vanguard Group, an estimated $76.3K added.
- The largest eXoZymes Inc seller in Q4 2025 was UBS Group, an estimated $63.7K sold.
Based on aggregated 13F filings for Q4 2025.